	Patients With Cancer					Patients Without Cancer					Interaction ^d	
	No. of	Descri	otive by				Descriptive by Group ^c					
Outcome	Patients/	Group ^c			n	Valid n ^b	Inter-		ß	n	ß	n
	No. of		Inter-	β							Р	
	Cliniciansb	Control	vention				Control	Vention				
Aim 1: Events at Target	Cirriciaris		vention					vention				
Visit				1			1	1		1		
vioit.												
Occurrence of discussion ^e	160/74	0.207	0.706	1.492	< 0.001	235/91	0.395	0.767	1.052	< 0.001	0.404	0.201
Aim 2: Concordance at 3												
Months ^f	109/70	0.538	0.705	0.495	0.057	172/81	0.590	0.697	0.281	0.215	0.201	0.516
Aim 3: Depression and												
Anxiety				I			1	I	1	1		
Standard PHQ-8 score, 3	142/76	F 204	6 700	4 202	0.000	24 6 /00	4 5 7 0	E 454	0.400	0 704	4 457	0.057
months ^g	143/76	5.281	6.793	1.302	0.030	216/88	4.570	5.451	-0.182	0.724	1.457	0.057
Standard GAD-7 score, 3	145/74	2 401	דרד כ	1 6 2 2	0.021	221/02	2 6 2 0	2 01 1	0.005	0.140	2.266	0.016
months ^h	145/74	3.481	5./5/	1.023	0.021	221/92	2.030	3.011	-0.985	0.140	2.300	0.010
Standard PHQ-8 score, 6	112/65	5 001	6 221	0 5 2 0	0 5 2 1	201/20	1 676	5 770	0 1 1 9	0 821	0.247	0 705
months ^g	115/05	5.091	0.231	0.323	0.331	201/03	4.070	5.775	0.110	0.031	0.247	0.755
Standard GAD-7 score, 6	119/67	3 689	3 385	-0 148	0.858	208/89	2 698	3 370	-0 221	0 742	-0 349	0 742
months ^h	113/07	5.005	5.505	0.140	0.000	200/05	2.000	5.570	0.221		0.045	U., 72

Table G.1. Association of Randomization Group With Study Outcomes, Comparing Patients With and Without Cancer^a

a Results were based on complex regression models with patients clustered under clinicians. All models included automatic adjustment for patient age, gender, and racial/ethnic minority status.

b Number of patients/number of clinician clusters.

c For binary outcomes, the descriptives show the proportion of the group with the outcome. For composite scores, the descriptives represent the mean value of the score at follow-up.

d Test for stratification group as an effect modifier of the association between the randomization group and the outcome. This statistic was based on a model using data from both disease groups, and with the randomization group indicator, the binary disease group indicator, and the product of the 2 indicators as predictors, along with the adjustments used in the stratified models. The coefficient and *P* value are for the product term.

e Binary outcome modeled with probit regression, estimated with weighted least squares estimator with mean and variance adjustment.

f Binary outcome (1 = treatment preference and actual treatment at 3 months were both life extension or comfort care; 0 = treatment preference at 3 months was life extension and actual treatment was comfort care, or the reverse; or patient wasn't sure about preference or actual treatment). In addition to the adjustments for patient gender, age, and racial/ethnic minority status, adjustment was automatically made for treatment preference at 3 months (life extension or comfort care); patients with other values on this adjustment variable were excluded.

g Robust linear regression model, estimated with restricted maximum likelihood. In addition to the adjustments for patient gender, age, and racial/ethnic minority status, automatic adjustment was made for the scale score at baseline.

h Tobit regression model (scale score defined as censored from below), estimated with WLSMV. In addition to the adjustments for patient gender, age, and racial/ethnic minority status, automatic adjustment was made for the scale score at baseline.